🏛️ Verified NIH Record • Updated 2024-11-14

A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors (NCT05262400)

A PHASE 1B/2, OPEN-LABEL, MULTICENTER, DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTITUMOR ACTIVITY OF PF-07220060 IN COMBINATION WITH PF-07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS

🔵 Active, Not Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic Sponsor: Pfizer

🩺 Plain-English Summary (8th-Grade Level)

The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07220060 and PF-07104091) in people with breast cancer. This clinical study consists of 2 parts (part 1 and part 2). In part 1, we are seeking participants who: * Have been diagnosed with Breast Cancer (BC) of either types: * Have HR+, HER2- BC * Refractory HR-positive/HER2-positive BC * Have other solid tumors other than BC In part 2, we are seeking participants who: -Have HR-positive/HER2-negative BC Part 1 will include increasing doses of PF-07220060 with PF-07104091. In part 2, participants will take 1 of 2 study medicine combinations. This will help us decide the highest amount of study medicines that can be safety given to people. All participants in this study will receive PF-07220060 with PF-07104091 by mouth. We will compare participant experiences to help us determine if PF-07220060 with PF-07104091 is safe and effective. Participants will take part in this study for about 2 years. During this time, they will receive the study medicine, an x-ray imaging, and will be observed for safety and effects of the study medicines.

Who can join: Review the eligibility criteria below.

Location: Administrative Address: UCLA Hematology/Oncology — Los Angeles, California

Age range: 18 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (51 Sites)

Showing the first 25 of 51 sites.

  • Administrative Address: UCLA Hematology/Oncology — Los Angeles, California
  • Ronald Reagan UCLA Medical Center — Los Angeles, California
  • UCLA Hematology/Oncology — Los Angeles, California
  • UCLA Hematology / Oncology-Parkside — Santa Monica, California
  • UCLA Hematology/Oncology-Santa Monica — Santa Monica, California
  • Massachusetts General Hospital — Boston, Massachusetts
  • START Midwest — Grand Rapids, Michigan
  • Saint Luke's Cancer Institute — Kansas City, Missouri
  • Texas Oncology-Baylor Charles A. Sammons Cancer Center — Dallas, Texas
  • The University of Texas MD Anderson Cancer Center — Houston, Texas
  • Swedish Medical Center — Seattle, Washington
  • Swedish Medical Center — Seattle, Washington
  • Clinica Viedma S. A — Viedma, Río Negro Province
  • Centro Oncologico Korben — Buenos Aires,
  • Clínica Universitaria Reina Fabiola — Córdoba,
  • Fundación CORI para la Investigación y Prevención del Cáncer — La Rioja,
  • ONCOSITE - Centro de Pesquisa Clinica em Oncologia — Ijuí, Rio Grande do Sul
  • Centro Gaucho Integrado De Oncologia, Hematologia, Ensino E Pesquisa — Porto Alegre, Rio Grande do Sul
  • Centro de Pesquisa Clínica - Área Administrativa — Porto Alegre, Rio Grande do Sul
  • Fundação Pio XII - Hospital de Câncer de Barretos — Barretos, São Paulo
  • Clínica de Pesquisas e Centro de Estudos em Oncologia Ginecológica e Mamária Ltda — São Paulo,
  • Multiprofile Hospital for Active Treatment Serdika EOOD — Sofia, Sofia (stolitsa)
  • Specialized Hospital for Active Treatment of Oncology - Haskovo — Haskovo,
  • Complex Oncology Center - Plovdiv EOOD — Plovdiv,
  • Multiprofile Hospital for Active Treatment Serdika EOOD — Sofia,

💰 Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Breast Cancer

Explore by condition: All Breast Cancer clinical trials

💡 How to Participate

  1. Check the checklist above to see if you may qualify.
  2. Review the official NIH record below to find the coordinating site.
  3. Ask about the visit schedule, what is covered at no cost, and any travel support.
  4. Confirm with your own doctor before making a decision.
🏛️ View Official NIH Record ↗